We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Is PCR Useful for the Clinical Diagnosis of Lyme Disease?

By LabMedica International staff writers
Posted on 04 Jul 2012
Although polymerase chain reaction (PCR)-based assays are being used more often in clinical settings, in general PCR is not useful for the diagnosis of Lyme disease. More...
Two-tiered serology remains the mainstay of laboratory testing for Lyme disease.

Dr. Christina Nelson, Medical Officer in the Bacterial Diseases Branch of Centers for Disease Control and Prevention (CDC; Atlanta, GA, USA) Division of Vector-Borne Disease, spoke about the appropriate use of polymerase chain reaction assays (PCR) in the clinical diagnosis and management of Lyme disease.

PCR testing has limitations. For example, DNA testing does not distinguish between living and dead organisms, and laboratory contamination with amplified DNA poses a risk for false-positive results.

Borrelia burgdorferi, the spirochete that causes Lyme disease, concentrates in collagen-rich connective tissues. Although spirochetes initially disseminate from the site of an infected tick bite via the blood, the bloodborne phase is relatively brief and the concentration of spirochetes is quite low.

PCR detects Borrelia DNA in the blood of fewer than half of patients in the early acute stage of disease when the erythema migrans rash is present. By the time symptoms of Lyme disease have been present for a month or more, spirochetes can no longer be found in blood. Similarly, PCR testing of cerebral spinal fluid (CSF) specimens is not clinically useful. PCR testing of CSF is positive in only about one third of US patients with early neuroborreliosis, and it is even less sensitive in patients with late neurologic disease. Urine is not a suitable sample for PCR testing at any stage of Lyme disease.

Borrelia burgdorferi can be detected by PCR in biopsy samples of infected skin, synovial tissue, or synovial fluid. These tissues are sometimes tested as part of a research study or to assess treatment response in a patient with previously confirmed Lyme arthritis.

However, skin biopsy is not generally recommended because patients with erythema migrans can be reasonably diagnosed and treated on the basis of history and clinical signs alone. The utility of testing synovial fluid is not well established and should be considered only under special circumstances.

Related Links:

Centers for Disease Control and Prevention



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Automatic Western Blot Analyzer
Tenfly Phoenix Blot Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.